Toggle Offcanvas
...
 
Dapagliflozin Tenders

Dapagliflozin Tenders

View Dapagliflozin tenders, RFPs and contracts. Bid on readily available Dapagliflozin tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Dapagliflozin tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Dapagliflozin.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Dapagliflozin market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Dapagliflozin tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

25 Live Notices for Dapagliflozin Tenders

Showing 1 to 20

Open House Contracts 2025-1
country Germany
posting date11 Mar 2025
deadline02 May 2025
Buy Dapagliflozin 10Mg Tab
country Jordan
posting date03 Mar 2025
deadline23 Mar 2025
Deruxtecan Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 160 MG Pharmaceutical Form: Injectable Lyophilized Powder; Crizotinib Concentration*: 250 MG; Enzalutamide Concentration: 40 MG; Ocrelizumab Concentration: 30 MG/ML Pharmaceutical Form: Solution for Infusion; Dapagliflozin Concentration: 10 MG; Evolocumab Concentration: 140 MG/ML Pharmaceutical Form: Injectable Solution Additional: With Applicator Pen; Ruxolitinib Concentration
country Brazil
posting date01 Mar 2025
deadline12 Mar 2025
Pharmaceutical Discount Agreements From February 1, 2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date12 Dec 2024
deadline02 Dec 2026
Medicines Containing The Active Ingredient Dapagliflozin (Atc: A10Bk01)
country Germany
posting date27 Aug 2024
deadline31 Jul 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin + Metformin, Atc A10Bd15 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date19 Aug 2024
deadline05 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin, Atc A10Bk01 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date19 Aug 2024
deadline05 Aug 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dapagliflozin, Atc A10Bk01 (Obo) For The Period 01.10.2024 - 30.09.2026
country Germany
posting date17 Aug 2024
deadline05 Aug 2026
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date17 Jun 2023
deadline31 Jul 2025
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date17 Jun 2023
deadline31 Jul 2025
Open House Original Discount Agreements 2023-20 - Metformin/Dapagliflozin (Drug Combination)
country Germany
posting date15 Jun 2023
deadline31 Jul 2025
Conclusion Of Non-Exclusive Discount Agreements According To § 130A Abs. 8 Sgb V For The Active Ingredient Dapagliflozin
country Germany
posting date10 May 2023
deadline09 May 2025
Conclusion Of Non-Exclusive Discount Agreements According To § 130A Abs. 8 Sgb V For The Active Ingredient Dapagliflozin
country Germany
posting date09 May 2023
deadline09 May 2025
Completion Of A Non-Excl. Discount Agreement According To § 130C Paragraph 1 Sgb V For Dapagliflozin, Atc Code: A10Bk01 For The Period From 06/01/2023 To 05/31/2025
country Germany
posting date27 Apr 2023
deadline04 Apr 2025
Completion Of A Non-Excl. Discount Agreement According To § 130C Paragraph 1 Sgb V For Dapagliflozin, Atc Code: A10Bk01 For The Period From 06/01/2023 To 05/31/2025
country Germany
posting date26 Apr 2023
deadline04 Apr 2025
Saxagliptin Og Dapagliflozin Tabletter Ba1.7.B
country Denmark
posting date27 Jan 2025
deadline01 Apr 2025
Metformin Og Dapagliflozin Tabletter Ba1.7.B
country Denmark
posting date27 Jan 2025
deadline01 Apr 2025
Bidding For The Purchase Of Dapagliflozin 10 Mg Film-Coated Tablet By Electronic Bidding Method
country Thailand
posting date14 Jan 2025
deadline13 Jan 2026
"Pharmaceutical Products" (Medicinal Charcoal), Dapagliflosin (Dapagliflozin), Empagliflosin (Empagliflozin), Folic Acid (Folic Acid), Norepinephrine (Noradrenerna, Norepinephrine (Norepineal. Dinitrate (Isosorbide Dinitrate), Dexpanthenol, Dexamethasone . Still
country Ukraine
posting date28 Feb 2025
deadline15 Mar 2025
Aceclofenac 100 Mg Plus Paracetamol 325 To 500 Mg Plusserratiopeptidase 10 Mgtab , Levo Salbutamol 200 Mcginhaler , Ondansetron Syp 2 Mg Per 5Ml In Bott Of 30 Ml ,Tenofovir 300 Mg Tab Plus Tab Lamivudine 150 Mg Plustab Efaverinz 600 , Dapagliflozin 10 Mg Tab ,Ursodeoxycholic Acid Sr 300 Mg Tab , Tab Betahistine 16Mg , Desvenlafaxine Extended Release 50 Mg Tab , Vitaminb12 500 Mcg Per Ml Inj Methylcobalamine , Diclofenacsodium Suppository 75 Mg , Inj Thiamine 100 Mg Per Ml Quantity: 14175
country India
posting date12 Mar 2025
deadline01 Apr 2025

Share Share this page